Merger

Arkansas-based Home BancShares is buying its way into Tennessee's booming economy. We dissect the 'triple accretive' deal to acquire Mountain Commerce.

Vyome's positive Phase 2 data targets a silent suffering in cancer care. This analysis explores its strategy to dominate a potential $1 billion market.

TotalEnergies is creating the UK's largest independent oil producer. A bold bet on fossil fuel efficiency or a contradiction to its green energy goals?

A legal fight over attorney fees in the Hess-Chevron deal reveals a costly risk in M&A. Here's why healthcare execs and investors should pay attention.

Hedge fund Balyasny Asset Management reveals a major stake in the Unite-Empiric takeover, signaling a high-stakes arbitrage play amid regulatory scrutiny.

A shareholder lawsuit challenges Comerica's $10.9B sale to Fifth Third, citing a rushed process, CEO self-interest, and an undervalued price.

A PE firm's operational overhaul of a corporate carve-out leads to a strategic sale, highlighting the consolidation and tech trends reshaping security.

After its DMD drug trial sent shares soaring over 370%, Capricor Therapeutics is raising $75M. A look at the high-stakes strategy to fund a breakthrough.

A regulatory filing shows hedge fund Balyasny's active trading in Avadel Pharma, exposing a merger arbitrage strategy amid a fierce bidding war.

The medtech giant projects robust growth with an ambitious pipeline, but a high-stakes regulatory showdown over a key acquisition could redefine its future.